
Validea's guru fundamental report rates UnitedHealth Group (UNH) at 77% using its Martin Zweig Growth Investor model, positioning it just below the 80% threshold for 'some interest' according to this strategy. While UNH passes on key metrics such as P/E ratio, sales growth, and current quarter earnings, it notably fails on consistent earnings growth acceleration and revenue growth in relation to EPS growth, indicating some inconsistency in the persistent accelerating growth sought by the Zweig model.
UnitedHealth Group (UNH) scores a 77% on Validea's Martin Zweig Growth Investor model, positioning it as a borderline candidate just below the 80% threshold that signals notable interest. The analysis reveals a company with several fundamental strengths, including a passing grade on its P/E ratio, sales growth rate, earnings persistence, long-term EPS growth, and current quarter earnings performance. Notably, the company's current quarter EPS growth exceeds that of the prior three quarters, and insider transactions are viewed favorably, suggesting management confidence. However, the model highlights critical weaknesses that temper a purely bullish outlook. UNH fails on key acceleration metrics, specifically its earnings growth rate over the past several quarters and the fact its current EPS growth does not surpass its historical growth rate. Furthermore, the company fails the test for revenue growth in relation to EPS growth, which can indicate that profit growth is not being fully supported by top-line expansion. This creates a mixed picture of a fundamentally sound company that currently lacks the consistent, accelerating growth profile required to fully satisfy the rigorous Zweig strategy.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment